FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FENNEC PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.27+0.29 (+2.91%)
Close on Oct 19, 2026
- Market cap
- $374.14M
- P/E (TTM)
- –
- Dividend yield
- –
FENNEC PHARMACEUTICALS INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEDMARK product sales, net | $17.16M | – | – | – | $9.65M | – | – | – | – | – | – | – | 96.0% | +77.8% |
| Other revenue | $710.00K | – | – | – | – | – | – | – | – | – | – | – | 4.0% | – |
| PEDMARK | – | $15.11M | $13.78M | $12.46M | $9.65M | $8.75M | $7.93M | $6.97M | $7.26M | $7.42M | $9.74M | $6.52M | – | – |
By region
From the segment and revenue-disaggregation notes of Fennec Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.